Home › Duchenne Muscular Dystrophy
Pag-aaral pangklinika para sa Duchenne Muscular Dystrophy na nagre-recruit sa U.S.
26 pag-aaral para sa Duchenne Muscular Dystrophy ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Little Rock, AR7 pag-aaral
- Boston, MA5 pag-aaral
- Chicago, IL5 pag-aaral
- Washington, DC5 pag-aaral
- Durham, NC5 pag-aaral
- Sacramento, CA5 pag-aaral
- Gainesville, FL5 pag-aaral
- Columbus, OH4 pag-aaral
- Nashville, TN4 pag-aaral
- Portland, OR3 pag-aaral
- Seattle, WA3 pag-aaral
- Mountain View, CA3 pag-aaral
- St. Louis, MO3 pag-aaral
- Cincinnati, OH3 pag-aaral
- Los Angeles, CA3 pag-aaral
- Norfolk, VA3 pag-aaral
Ayos sa estado
- Arkansas7 pag-aaral
- California6 pag-aaral
- District of Columbia5 pag-aaral
- Florida5 pag-aaral
- Illinois5 pag-aaral
- Massachusetts5 pag-aaral
- Missouri3 pag-aaral
- New York4 pag-aaral
- North Carolina6 pag-aaral
- Ohio5 pag-aaral
- Oregon3 pag-aaral
- Pennsylvania4 pag-aaral
- Tennessee4 pag-aaral
- Texas5 pag-aaral
- Virginia4 pag-aaral
- Washington3 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)
Nagre-recruitPhase 3
Edad 7 hanggang 11 · Kalalakihan · Na-update Set 28, 2026 · NCT07160634Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT
Nagre-recruitObservasyonal na pag-aaral
Edad 2 pataas · Kalalakihan · Na-update Set 24, 2026 · NCT06564974A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort
Nagre-recruitPhase 1
Edad 2 pataas · Kalalakihan · Na-update Set 11, 2026 · NCT04626674Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy
Nagre-recruitPhase 1
Edad 8 hanggang 18 · Kalalakihan · Na-update Ago 24, 2026 · NCT07172971The Baby Duchenne Study: Characterizing Developmental and Clinical Outcomes in the First Three Years in Children With Duchenne Muscular Dystrophy
Nagre-recruitObservasyonal na pag-aaral
0 Days – 3 Years · Kalalakihan · Na-update Ago 19, 2026 · NCT07092540Evaluating VM100 Nutritional Supplement for Improving Quality of Life in Duchenne Muscular Dystrophy Patients
Nagre-recruit
Edad 6 pataas · Kalalakihan · Na-update Ago 17, 2026 · NCT07766980Once Weekly Infant Corticosteroid Trial for DMD
Nagre-recruitPhase 4
1 Month – 30 Months · Kalalakihan · Na-update Ago 14, 2026 · NCT05412394Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Hul 28, 2026 · NCT07674758A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)
Nagre-recruitPhase 1/2
Edad 0 hanggang 17 · Kalalakihan · Na-update Hul 8, 2026 · NCT06138639A Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular Dystrophy
Nagre-recruitObservasyonal na pag-aaral
Edad 6 pataas · Lahat ng kasarian · Na-update Hul 2, 2026 · NCT07127978PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD)
Nagre-recruitPhase 1/2
Edad 2 hanggang 7 · Kalalakihan · Na-update Hun 23, 2026 · NCT07429240Duchenne Electronic Health Record Study
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update May 27, 2026 · NCT07609394Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)
Nagre-recruitPhase 3
Edad 4 hanggang 18 · Kalalakihan · Na-update May 27, 2026 · NCT07608432Wearable Technology to Evaluate Hyperglycemia and HRV in DMD
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 10 pataas · Kalalakihan · Na-update May 22, 2026 · NCT06124196Vasodilator and Exercise Study for DMD (VASO-REx)
Nagre-recruitPhase 2
Edad 6 pataas · Kalalakihan · Na-update May 15, 2026 · NCT06290713The Duchenne Registry
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update May 8, 2026 · NCT02069756Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 5 pataas · Lahat ng kasarian · Na-update Abr 9, 2026 · NCT06839469Urinary Titin Biomarker in DMD
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
Edad 2 hanggang 10 · Kalalakihan · Na-update Abr 8, 2026 · NCT07332013Trial of Cell Based Therapy for DMD
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 4, 2026 · NCT06692426Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Nagre-recruitPhase 1/2
Edad 4 hanggang 18 · Kalalakihan · Na-update Dis 15, 2025 · NCT04906460Extracellular RNA Biomarkers of Duchenne Muscular Dystrophy
Nagre-recruitObservasyonal na pag-aaral
Edad 5 pataas · Lahat ng kasarian · Na-update Nob 24, 2025 · NCT05016908Biomarker Development for Muscular Dystrophies
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 5 pataas · Lahat ng kasarian · Na-update Nob 24, 2025 · NCT05019625Wearable Technology to Evaluate Hyperglycemia and HRV in DMD - Longitudinal Aim
Nagre-recruitObservasyonal na pag-aaral
Edad 10 pataas · Kalalakihan · Na-update Nob 6, 2025 · NCT06093100Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 5 hanggang 62 · Kalalakihan · Na-update Okt 15, 2025 · NCT01484678DMD Voice: Qualitative Interviews With Patients and Caregivers
Nagre-recruitObservasyonal na pag-aaral
Edad 10 pataas · Kalalakihan · Na-update Abr 30, 2025 · NCT06925269Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.